Alkermes plc. vs Moderna
Moderna is the larger business, with $1.94bn of revenue in fiscal 2025 against $1.48bn for Alkermes plc. (1.3 times as much). Alkermes plc. grew faster (-5.2% against -39.9%). Alkermes plc. kept more of each dollar of sales as profit: a net margin of 16.4% against -145.2%. Alkermes plc. carries less debt relative to equity (0.0% against 6.8%).
| Latest fiscal year | Alkermes plc.ALKS, 2025 | ModernaMRNA, 2025 |
|---|---|---|
| Revenue | $1.48bn | $1.94bn |
| Revenue growth | -5.2% | -39.9% |
| Net income | $242m | −$2.82bn |
| Operating margin | 17.2% | -158.1% |
| Net margin | 16.4% | -145.2% |
| Return on equity | 14.7% | -28.9% |
| Free cash flow | $480m | −$2.06bn |
| Cash | $389m | $2.60bn |
| Total debt | $0 | $590m |
| Debt to equity | 0.0% | 6.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $2.0m |
| Employees | 2,050 | 4,700 |
| Market value | $7.84bn | $90.21bn |
| Price vs our value range | Within our value range | — |
| Moat score | 63 (Moderate) | 26 (Weak) |
| Insider trades, 12 months | 0 buys, 33 sales | 0 buys, 22 sales |